Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
0.79
% (maximum dilution rate)Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Issuance of Stock Options (Share Acquisition Rights) (株式会社ステムリム Series 19 Share Acquisition Rights (A))
Who receives how much
4,989 share acquisition rights, representing 498,900 underlying common shares (100 shares per right)
47 of the Company's executive officers and employees: 4,989 rights
The lower thin line represents the existing number of shares to which these shares will be added.
Nil per stock acquisition right
Total issue value
No consideration
Amount of funds to be raised
Total amount to be paid: ¥0; estimated net proceeds: ¥0
発行済株式総数
Maximum 0.79% (based on 62,681,200 issued shares as of 9 September 2026)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Closing price on the allotment date × 1.025 (fractions of less than ¥1 rounded up). Adjusted for share splits or consolidations, the issuance of new shares or disposal of treasury shares at a price below market value, mergers and other events. The lower limit of the adjustment is Not disclosed.
Exercise period
From 11 September 2028 to 9 September 2036
Number of Stock Acquisition Rights
Total issued: 4,989 rights. Unexercised balance: Not disclosed.
Reason for acquisition without consideration
If a merger in which the Company is the disappearing company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary, is approved at a shareholders meeting. If a holder of the share acquisition rights no longer meets the exercise conditions and can no longer exercise the rights, or waives the rights. The Company may cancel the share acquisition rights it holds at any time free of charge.
Categories and Number of Persons Covered
47 of the Company's executive officers and employees: 4,989 rights
Intended allottee's holding policy
The acquisition of the stock acquisition rights by transfer requires the approval of the company's Board of Directors.
Basis for determining the amount to be paid
The exercise price is the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the allotment date multiplied by 1.025, or the closing price on the most recent preceding trading day if no trade is concluded. This represents a 2.5% premium to the closing price.
Procedures under the Corporate Code of Conduct
The issuance was resolved by the Board of Directors at its meeting held on 9 September 2026, based on a resolution of the annual shareholders meeting held on 22 October 2025. Whether an independent third-party opinion was obtained is Not disclosed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of Stock Options (Share Acquisition Rights) (株式会社ステムリム Series 19 Share Acquisition Rights (A)) |
| Number of shares to be issued or disposed of | 4,989 share acquisition rights, representing 498,900 underlying common shares (100 shares per right) |
| Issue price and disposal price | Nil per stock acquisition right |
| Total issue value | No consideration |
| Amount of funds to be raised | Total amount to be paid: ¥0; estimated net proceeds: ¥0 |
| Intended allottee | 47 of the Company's executive officers and employees: 4,989 rights |
| Intended allottee's holding policy | The acquisition of the stock acquisition rights by transfer requires the approval of the company's Board of Directors. |
| Dilution Rate | Maximum 0.79% (based on 62,681,200 issued shares as of 9 September 2026) |
| Total number of issued shares | 62,681,200 shares → Not disclosed |
| Basis for determining the amount to be paid | The exercise price is the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the allotment date multiplied by 1.025, or the closing price on the most recent preceding trading day if no trade is concluded. This represents a 2.5% premium to the closing price. |
| Exercise price | Closing price on the allotment date × 1.025 (fractions of less than ¥1 rounded up). Adjusted for share splits or consolidations, the issuance of new shares or disposal of treasury shares at a price below market value, mergers and other events. The lower limit of the adjustment is Not disclosed. |
| Exercise period | From 11 September 2028 to 9 September 2036 |
| Number of Stock Acquisition Rights | Total issued: 4,989 rights. Unexercised balance: Not disclosed. |
| Reason for acquisition without consideration | If a merger in which the Company is the disappearing company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary, is approved at a shareholders meeting. If a holder of the share acquisition rights no longer meets the exercise conditions and can no longer exercise the rights, or waives the rights. The Company may cancel the share acquisition rights it holds at any time free of charge. |
| Categories and Number of Persons Covered | 47 of the Company's executive officers and employees: 4,989 rights |
| Procedures under the Corporate Code of Conduct | The issuance was resolved by the Board of Directors at its meeting held on 9 September 2026, based on a resolution of the annual shareholders meeting held on 22 October 2025. Whether an independent third-party opinion was obtained is Not disclosed. |
Items this document does not state (12)
Estimated issuance expensesSpecific use of fundsPayment dateTransfer restriction periodConditions for lifting transfer restrictionsTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To increase motivation and morale to contribute to advances in research and development, thereby contributing to higher corporate value, and to secure outstanding talent.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.